Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults.

Eliakim-Raz, Noa; Stemmer, Amos; Ghantous, Nassem; Ness, Asaf; Awwad, Muhammad; Leibovici-Weisman, Yaara; Stemmer, Salomon M · JAMA Netw Open · 2022

prospective_cohort · Level II

Where this comes from

Abstract

This cohort study evaluates the response to a third and fourth SARS-CoV-2 BNT162b2 vaccine dose among individuals aged 60 years or older by evaluating antispike immunoglobulin G antibody titers before and after each dose.

Medical subject headings